CD163 and COVID-19: The evaluation of sCD163 plasmatic levels in COVID-19 subjects stratified according to WHO guidelines, into three groups (critical, severe and mild) showed a higher sCD163 plasmatic level in the critical group compared to the mild one (p=0.004).